Comparative Pharmacology
Head-to-head clinical analysis: GVS versus KANTREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GVS versus KANTREX.
GVS vs KANTREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GVS is not a recognized drug. No mechanism of action available.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis and causing mRNA misreading.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
15 mg/kg/day IM or IV divided every 8-12 hours (not to exceed 1.5 g/day)
None Documented
None Documented
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; clinically significant accumulation in renal impairment requires monitoring
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Renal: 80-100% as unchanged drug via glomerular filtration; fecal: <1%
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic